The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.

The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer Prev Res (Phila). 2010 Nov; 3(11):1417-26.

View in: PubMed

subject areas

Animals
Animals
Antineoplastic Agents
Antineoplastic Agents
Blotting, Western
Blotting, Western
Carcinoma in Situ
Carcinoma in Situ
Carcinoma, Pancreatic Ductal
Carcinoma, Pancreatic Ductal
Disease Models, Animal
Disease Models, Animal
Disease Progression
Disease Progression
ErbB Receptors
ErbB Receptors
Fluorescent Antibody Technique
Fluorescent Antibody Technique
Immunohistochemistry
Immunohistochemistry
Male
Male
Mice
Mice
Mice, Inbred C57BL
Mice, Inbred C57BL
Mice, Transgenic
Mice, Transgenic
Pancreatic Neoplasms
Pancreatic Neoplasms
Quinazolines
Quinazolines
Reverse Transcriptase Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction

authors with profiles

Venkateshwar Madka